EU/3/20/2282: Orphan designation for the treatment of Duchenne muscular dystrophy
Viltolarsen
Table of contents
Overview
On 4 June 2020, orphan designation EU/3/20/2282 was granted by the European Commission to Medpace Finland Oy, Finland, for viltolarsen for the treatment of Duchenne muscular dystrophy.
Key facts
Active substance |
Viltolarsen
|
Intended use |
Treatment of Duchenne muscular dystrophy
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/20/2282
|
Date of designation |
04/06/2020
|
Sponsor |
Medpace Finland Oy |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
Date | Update |
---|---|
May 2023 | The sponsor's address was updated. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: